GlaxoSmithKline: Purpura trials

The registry lists 12 Purpura studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 4Phase 3 1Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT01098487Phase 4Results posted
• Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00908037Phase 2Results posted
• Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)CompletedNCT00424177Phase 2Results posted
• RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With EltrombopagCompletedNCT00370331Phase 3Results posted
• A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.WithdrawnNCT01440361Phase 2
• Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food EffectCompletedNCT01072162Phase 1
• Promacta Pregnancy RegistryCompletedNCT01064336
• Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of EltrombopagCompletedNCT00688272Phase 1
• LENS - Long-term Eltrombopag Observational StudyCompletedNCT00643929
• Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal ImpairmentCompletedNCT00442871Phase 1
• Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic ImpairmentCompletedNCT00359463Phase 1
• SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00102739Phase 2